Therapeutic Potential of Fingolimod in Diabetes Mellitus and Its Chronic Complications

References

• Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. doi:10.1016/j.diabres.2021.109119
   PubMed Web of Science ®Google Scholar
• Yang XD, Yang YY. Ferroptosis as a novel therapeutic target for diabetes and its complications. Front Endocrinol. 2022;13:853822. doi:10.3389/fendo.2022.853822
   PubMed Web of Science ®Google Scholar
• Cole JB, Florez JC. Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol. 2020;16(7):377–390. doi:10.1038/s41581-020-0278-5
   PubMed Web of Science ®Google Scholar
• Entezari M, Hashemi D, Taheriazam A, et al. AMPK signaling in diabetes mellitus, insulin resistance and diabetic complications: a pre-clinical and clinical investigation. Biomed Pharmacother. 2022;146:112563. doi:10.1016/j.biopha.2021.112563
   PubMed Web of Science ®Google Scholar
• Susan Van D, Beulens JWJ, Yvonne T, Van Der S, Grobbee DE, Nealb B. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil. 2010;17(1_suppl):s3–s8. doi:10.1097/01.hjr.0000368191.86614.5a
   PubMedGoogle Scholar
• Yang M, Chen J, Chen L. The roles of mesenchymal stem cell-derived exosomes in diabetes mellitus and its related complications. Front Endocrinol. 2022;13:1027686. doi:10.3389/fendo.2022.1027686
   PubMed Web of Science ®Google Scholar
• Ng ML, Wadham C, Sukocheva OA. The role of sphingolipid signalling in diabetes-associated pathologies (Review). IntJ Mol Med. 2017;39(2):243–252. doi:10.3892/ijmm.2017.2855
   PubMed Web of Science ®Google Scholar
• Jessup F, Bonder CS, Pitson CM, Toby S, Coates H. The sphingolipid rheostat: a potential target for improving pancreatic islet survival and function. EMIDDT. 2011;11(4):262–272. doi:10.2174/187153011797881201
   Google Scholar
• Yazdi A, Ghasemi‐Kasman M, Javan M. Possible regenerative effects of fingolimod (FTY720) in multiple sclerosis disease: an overview on remyelination process. J Neurosci Res. 2020;98(3):524–536. doi:10.1002/jnr.24509
   PubMed Web of Science ®Google Scholar
• White C, Alshaker H, Cooper C, Winkler M, Pchejetski D. The emerging role of FTY720 (Fingolimod) in cancer treatment. Oncotarget. 2016;7(17):23106–23127. doi:10.18632/oncotarget.7145
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang H. FTY720 in CNS injuries: molecular mechanisms and therapeutic potential. Brain Res Bull. 2020;164:75–82. doi:10.1016/j.brainresbull.2020.08.013
   PubMed Web of Science ®Google Scholar
• Yin Z, Fan L, Wei L, et al. FTY720 protects cardiac microvessels of diabetes: a critical role of S1P1/3 in diabetic heart disease. PLoS One. 2012;7(8):e42900. doi:10.1371/journal.pone.0042900
   PubMed Web of Science ®Google Scholar
• Gesualdo C, Balta C, Platania CBM, et al. Fingolimod and diabetic retinopathy: a drug repurposing study. Front Pharmacol. 2021;12:718902. doi:10.3389/fphar.2021.718902
   PubMed Web of Science ®Google Scholar
• Sood A, Fernandes V, Preeti K, Khot M, Khatri DK, Singh SB. Fingolimod alleviates cognitive deficit in type 2 diabetes by promoting microglial M2 polarization via the pSTAT3-jmjd3 axis. Mol Neurobiol. 2023;60(2):901–922. doi:10.1007/s12035-022-03120-x
   PubMed Web of Science ®Google Scholar
• Bravo GÁ, Cedeño RR, Casadevall MP, Ramió-Torrentà L. Sphingosine-1-Phosphate (S1P) and S1P signaling pathway modulators, from current insights to future perspectives. Cells. 2022;11(13):2058. doi:10.3390/cells11132058
   PubMed Web of Science ®Google Scholar
• Takabe K, Paugh SW, Milstien S, Spiegel S. “Inside-out” signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev. 2008;60(2):181–195. doi:10.1124/pr.107.07113
   PubMed Web of Science ®Google Scholar
• Huwiler A, Zangemeister-Wittke U. The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: recent findings and new perspectives. Pharmacol Ther. 2018;185:34–49. doi:10.1016/j.pharmthera.2017.11.001
   PubMed Web of Science ®Google Scholar
• Cartier A, Hla T. Sphingosine 1-phosphate: lipid signaling in pathology and therapy. Science. 2019;366(6463):eaar5551. doi:10.1126/science.aar5551
   PubMed Web of Science ®Google Scholar
• Stepanovska B, Huwiler A. Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases. Pharmacol Res. 2020;154:104170. doi:10.1016/j.phrs.2019.02.009
   PubMed Web of Science ®Google Scholar
• Boldizsar F, Tarjanyi O, Olasz K, et al. FTY720 (Gilenya) treatment prevents spontaneous autoimmune myocarditis and dilated cardiomyopathy in transgenic HLA-DQ8-BALB/c mice. Cardiovasc Pathol. 2016;25(5):353–361. doi:10.1016/j.carpath.2016.05.003
   PubMed Web of Science ®Google Scholar
• Commodaro AG, Peron JPS, Lopes CT, et al. Evaluation of experimental autoimmune uveitis in mice treated with FTY720. Invest Ophthalmol Vis Sci. 2010;51(5):2568. doi:10.1167/iovs.09-4769
   PubMed Web of Science ®Google Scholar
• Okazaki H, Hirata D, Kamimura T, et al. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. J Rheumatol. 2002;29(4):707–716.
   PubMed Web of Science ®Google Scholar
• Keul P, Tölle M, Lucke S, et al. The Sphingosine-1-Phosphate Analogue FTY720 reduces atherosclerosis in apolipoprotein E–deficient mice. Arteriosclerosis Thrombosis Vasc Biol. 2007;27(3):607–613. doi:10.1161/01.ATV.0000254679.42583.88
   PubMed Web of Science ®Google Scholar
• Fayyaz S, Japtok L, Kleuser B. Divergent role of Sphingosine 1-phosphate on insulin resistance. Cell Physiol Biochem. 2014;34(1):134–147. doi:10.1159/000362990
   PubMedGoogle Scholar
• He Q, Bo J, Shen R, et al. S1P signaling pathways in pathogenesis of type 2 diabetes. J Diabetes Res. 2021;2021:1–12. doi:10.1155/2021/1341750
   Web of Science ®Google Scholar
• Zhao Z, Choi J, Zhao C, Ma ZA. FTY720 normalizes hyperglycemia by stimulating β-cell in vivo regeneration in db/db mice through regulation of cyclin D3 and p57KIP2. J Biol Chem. 2012;287(8):5562–5573. doi:10.1074/jbc.M111.305359
   PubMed Web of Science ®Google Scholar
• Moon H, Chon J, Joo J, et al. FTY720 preserved islet β -cell mass by inhibiting apoptosis and increasing survival of β -cells in db/db mice: FTY720 preserves islet β -cell in mice. Diabetes Metab Res Rev. 2013;29(1):19–24. doi:10.1002/dmrr.2341
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Sasase T, Ishii Y, et al. The sphingosine‐1‐phosphate receptor modulator, FTY720, prevents the incidence of diabetes in Spontaneously Diabetic Torii rats. Clin Exp Pharma Physio. 2021;48(6):869–876. doi:10.1111/1440-1681.13405
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang X, An A, et al. Immunomodulator FTY720 improves glucose homeostasis and diabetic complications by rejuvenation of β ‐cell function in nonhuman primate model of diabetes. Fund Clin Pharm. 2022;36(4):699–711. doi:10.1111/fcp.12760
   PubMed Web of Science ®Google Scholar
• Kendall MR, Hupfeld CJ. FTY720, a sphingosine‐1‐phosphate receptor modulator, reverses high‐fat diet–induced weight gain, insulin resistance and adipose tissue inflammation in C57BL/6 mice. Diabetes Obesity Metab. 2008;10(9):802–805. doi:10.1111/j.1463-1326.2008.00910.x
   PubMed Web of Science ®Google Scholar
• Bruce CR, Risis S, Babb JR, et al. The sphingosine-1-phosphate analog FTY720 reduces muscle ceramide content and improves glucose tolerance in high fat-fed male mice. Endocrinology. 2013;154(1):65–76. doi:10.1210/en.2012-1847
   PubMed Web of Science ®Google Scholar
• Yang Z, Chen M, Fialkow LB, et al. The immune modulator FYT720 prevents autoimmune diabetes in nonobese diabetic mice☆. Clin Immunol. 2003;107(1):30–35. doi:10.1016/S1521-6616(02)00054-2
   PubMed Web of Science ®Google Scholar
• Penaranda C, Tang Q, Ruddle NH, Bluestone JA. Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs. Diabetes. 2010;59(6):1461–1468. doi:10.2337/db09-1129
   PubMed Web of Science ®Google Scholar
• Jörns A, Rath KJ, Terbish T, et al. Diabetes prevention by immunomodulatory FTY720 Treatment in the LEW.1AR1-iddm rat despite immune cell activation. Endocrinology. 2010;151(8):3555–3565. doi:10.1210/en.2010-0202
   PubMed Web of Science ®Google Scholar
• Fan L, Yan H. FTY720 attenuates retinal inflammation and protects blood–retinal barrier in diabetic rats. Invest Ophthalmol Vis Sci. 2016;57(3):1254. doi:10.1167/iovs.15-18658
   PubMed Web of Science ®Google Scholar
• Abdullah CS, Li Z, Wang X, Jin ZQ. Depletion of T lymphocytes ameliorates cardiac fibrosis in streptozotocin-induced diabetic cardiomyopathy. Int Immunopharmacol. 2016;39:251–264. doi:10.1016/j.intimp.2016.07.027
   PubMed Web of Science ®Google Scholar
• Xu H, Jin Y, Ni H, Hu S, Zhang Q. Sphingosine-1-phosphate receptor agonist, FTY720, restores coronary flow reserve in diabetic rats. Circ J. 2014;78(12):2979–2986. doi:10.1253/circj.CJ-14-0521
   PubMed Web of Science ®Google Scholar
• English D, Welch Z, Kovala AT, et al. Sphingosine 1‐phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis. FASEB j. 2000;14(14):2255–2265. doi:10.1096/fj.00-0134com
   PubMed Web of Science ®Google Scholar
• Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74(5):1124–1136. doi:10.1161/01.CIR.74.5.1124
   PubMed Web of Science ®Google Scholar
• Rana A, Sharma S. Mechanism of sphingosine-1-phosphate induced cardioprotection against I/R injury in diabetic rat heart: possible involvement of glycogen synthase kinase 3 β and mitochondrial permeability transition pore. Clin Exp Pharmacol Physiol. 2016;43(2):166–173. doi:10.1111/1440-1681.12516
   PubMed Web of Science ®Google Scholar
• Becher PM, Lindner D, Fröhlich M, Savvatis K, Westermann D, Tschöpe C. Assessment of cardiac inflammation and remodeling during the development of streptozotocin-induced diabetic cardiomyopathy in vivo: a time course analysis. IntJ Mol Med. 2013;32(1):158–164. doi:10.3892/ijmm.2013.1368
   PubMed Web of Science ®Google Scholar
• Ivanova E, Kovacs-Oller T, Sagdullaev BT. Vascular pericyte impairment and connexin43 gap junction deficit contribute to vasomotor decline in diabetic retinopathy. J Neurosci. 2017;37(32):7580–7594. doi:10.1523/JNEUROSCI.0187-17.2017
   PubMed Web of Science ®Google Scholar
• Eshaq RS, Aldalati AMZ, Alexander JS, Harris NR. Diabetic retinopathy: breaking the barrier. Pathophysiology. 2017;24(4):229–241. doi:10.1016/j.pathophys.2017.07.001
   PubMedGoogle Scholar
• Simó R, Simó-Servat O, Bogdanov P, Hernández C. Neurovascular unit: a new target for treating early stages of diabetic retinopathy. Pharmaceutics. 2021;13(8):1320. doi:10.3390/pharmaceutics13081320
   PubMed Web of Science ®Google Scholar
• Whitcup SM, Cidlowski JA, Csaky KG, Ambati J. Pharmacology of Corticosteroids for Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2018;59(1):1. doi:10.1167/iovs.17-22259
   PubMed Web of Science ®Google Scholar
• Stewart MW. Treatment of diabetic retinopathy: recent advances and unresolved challenges. World J Diabetes. 2016;7(16):333. doi:10.4239/wjd.v7.i16.333
   PubMed Web of Science ®Google Scholar
• Tang L, Xu GT, Zhang JF. Inflammation in diabetic retinopathy: possible roles in pathogenesis and potential implications for therapy. Neural Regen Res. 2023;18(5):976. doi:10.4103/1673-5374.355743
   PubMed Web of Science ®Google Scholar
• Chernykh V, Varvarinsky E, Smirnov E, Chernykh D, Trunov A. Proliferative and inflammatory factors in the vitreous of patients with proliferative diabetic retinopathy. Indian J Ophthalmol. 2015;63(1):33. doi:10.4103/0301-4738.151464
   PubMed Web of Science ®Google Scholar
• Boss JD, Singh PK, Pandya HK, et al. Assessment of neurotrophins and inflammatory mediators in vitreous of patients with diabetic retinopathy. Invest Ophthalmol Vis Sci. 2017;58(12):5594. doi:10.1167/iovs.17-21973
   PubMed Web of Science ®Google Scholar
• Capitão M, Soares R. Angiogenesis and inflammation crosstalk in diabetic retinopathy. J of Cellular Biochem. 2016;117(11):2443–2453. doi:10.1002/jcb.25575
   PubMed Web of Science ®Google Scholar
• Vinores SA, Xiao WH, Shen J, Campochiaro PA. TNF-α is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage. J Neuroimmunol. 2007;182(1–2):73–79. doi:10.1016/j.jneuroim.2006.09.015
   PubMed Web of Science ®Google Scholar
• Huang H, Gandhi JK, Zhong X, et al. TNFα Is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. Invest Ophthalmol Vis Sci. 2011;52(3):1336. doi:10.1167/iovs.10-5768
   PubMed Web of Science ®Google Scholar
• Yun JH. Interleukin-1β induces pericyte apoptosis via the NF-κB pathway in diabetic retinopathy. Biochem Biophys Res Commun. 2021;546:46–53. doi:10.1016/j.bbrc.2021.01.108
   PubMed Web of Science ®Google Scholar
• Yao Y, Li R, Du J, Long L, Li X, Luo N. Interleukin-6 and diabetic retinopathy: a systematic review and meta-analysis. Curr Eye Res. 2019;44(5):564–574. doi:10.1080/02713683.2019.1570274
   PubMed Web of Science ®Google Scholar
• Miyamoto K, Ogura Y. Pathogenetic potential of leukocytes in diabetic retinopathy. Semi Ophthalmol. 1999;14(4):233–239. doi:10.3109/08820539909069542
   PubMedGoogle Scholar
• Maisto R, Gesualdo C, Trotta MC, et al. Melanocortin receptor agonists MCR 1-5 protect photoreceptors from high-glucose damage and restore antioxidant enzymes in primary retinal cell culture. J Cell Mol Med. 2017;21(5):968–974. doi:10.1111/jcmm.13036
   PubMed Web of Science ®Google Scholar
• Rossi S, Maisto R, Gesualdo C, et al. Activation of melanocortin receptors MC 1 and MC 5 attenuates retinal damage in experimental diabetic retinopathy. Mediators Inflammation. 2016;2016:1–13. doi:10.1155/2016/7368389
   Web of Science ®Google Scholar
• Danta CC, Boa AN, Bhandari S, Sathyapalan T, Xu SZ. Recent advances in drug discovery for diabetic kidney disease. Expert Opin Drug Discov. 2021;16(4):447–461. doi:10.1080/17460441.2021.1832077
   PubMed Web of Science ®Google Scholar
• Koch A, Pfeilschifter J, Huwiler A. Sphingosine 1-phosphate in renal diseases. Cell Physiol Biochem. 2013;31(6):745–760. doi:10.1159/000350093
   PubMedGoogle Scholar
• Deng Y, Lan T, Huang J, Huang H. Sphingosine Kinase-1/sphingosine 1-phosphate pathway in diabetic nephropathy. Chin Med J. 2014;127(16):3004–3010.
   PubMed Web of Science ®Google Scholar
• Kurano M, Tsukamoto K, Shimizu T, Hara M, Yatomi Y. Apolipoprotein M/sphingosine 1-phosphate protects against diabetic nephropathy. Transl Res. 2023;258:16–34. doi:10.1016/j.trsl.2023.02.004
   PubMed Web of Science ®Google Scholar
• Awad AS, Ye H, Huang L, et al. Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am J Physiol Renal Physiol. 2006;290(6):F1516–F1524. doi:10.1152/ajprenal.00311.2005
   PubMed Web of Science ®Google Scholar
• Bajwa A, Jo SK, Ye H, et al. Activation of Sphingosine-1-Phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury. J Am Soc Nephrol. 2010;21(6):955–965. doi:10.1681/ASN.2009060662
   PubMed Web of Science ®Google Scholar
• Awad AS, Rouse MD, Khutsishvili K, et al. Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes. Kidney Int. 2011;79(10):1090–1098. doi:10.1038/ki.2010.544
   PubMed Web of Science ®Google Scholar
• Esposito K, Maiorino MI, Bellastella G. Diabetes and sexual dysfunction: current perspectives. Diab Metab Synd Obes. 2014;95. doi:10.2147/DMSO.S36455
   PubMedGoogle Scholar
• Cui K, Ruan Y, Wang T, et al. FTY720 supplementation partially improves erectile dysfunction in rats with streptozotocin-induced type 1 diabetes through inhibition of endothelial dysfunction and corporal fibrosis. J Sex Med. 2017;14(3):323–335. doi:10.1016/j.jsxm.2017.01.006
   PubMed Web of Science ®Google Scholar
• Ennis GE, Saelzler U, Umpierrez GE, Moffat SD. Prediabetes and working memory in older adults. Brain Neurosci Adv. 2020;4:239821282096172. doi:10.1177/2398212820961725
   Google Scholar
• Miguez A, García-Díaz Barriga G, Brito V, et al. Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington’s disease by preventing p75 NTR up-regulation and astrocyte-mediated inflammation. Hum Mol Genet. 2015;24(17):4958–4970. doi:10.1093/hmg/ddv218
   PubMed Web of Science ®Google Scholar
• Hunter SF, Bowen JD, Reder AT. The direct effects of fingolimod in the central nervous system: implications for relapsing multiple sclerosis. CNS Drugs. 2016;30(2):135–147. doi:10.1007/s40263-015-0297-0
   PubMed Web of Science ®Google Scholar
• Bilbo S, Stevens B. Microglia: the brain’s first responders. Cerebrum. 2017;2017:14–17.
   Google Scholar
• Rom S, Zuluaga-Ramirez V, Gajghate S, et al. Hyperglycemia-driven neuroinflammation compromises BBB leading to memory loss in both Diabetes Mellitus (DM) type 1 and type 2 mouse models. Mol Neurobiol. 2019;56(3):1883–1896. doi:10.1007/s12035-018-1195-5
   PubMed Web of Science ®Google Scholar
• Sood A, Fernandes V, Preeti K, Khatri DK, Singh SB. Sphingosine 1 phosphate lyase inhibition rescues cognition in diabetic mice by promoting anti-inflammatory microglia. Behav Brain Res. 2023;446:114415. doi:10.1016/j.bbr.2023.114415
   PubMed Web of Science ®Google Scholar
• Lucaciu A, Brunkhorst R, Pfeilschifter J, Pfeilschifter W, Subburayalu J. The S1P–S1PR axis in neurological disorders—insights into current and future therapeutic perspectives. Cells. 2020;9(6):1515. doi:10.3390/cells9061515
   PubMed Web of Science ®Google Scholar